

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



MAR. 24 2004 3:30PM

AVENTIS US PAT DEPT

NO. 0801 P. 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
MAURY, et al.

Examiner: Not Yet Known

Art Unit: Not Yet Known

Application No.: 10/726,721

Filed: December 3, 2003

Title: **FEBP1 PROTEIN VECTOR HOST
CELLS AND METHOD FOR MAKING
FEBP1 PROTEIN**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450, on

March 24, 2004

Date of Deposit

Jonas Herre Sr.
Signature

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Mail Stop Missing Parts
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Sirs:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", which was mailed March 19, 2004, and which indicated that this application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

Applicants submit herewith a statement regarding content of paper and computer readable copies and reference to another application of file pursuant to 37 CFR 1.821(e) and 1.821 (f).

The Commissioner is hereby authorized to charge any additional fee which may be required by this paper, or credit any overpayment to Deposit Account No. 18-1982. Two (2) duplicate copies of this sheet are enclosed.

Respectfully submitted,


Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3444
Telefax: 908-231-2626

Docket No. USST00004 US DIV



MAR 24, 2004 3:30PM

AVENTIS US PAT DEPT

NO. 0801 P. 1

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICEApplicants Docket Number:
USST00004 US DIVApplicants:
MAURY, et al.Serial No.
10/726,721Filing Date:
December 3, 2003Title of Invention:
FEBP1 PROTEIN VECTOR HOST CELLS AND METHOD FOR MAKING FEBP1 PROTEIN

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, Missing Parts, at 703-746-4060, onDate of Deposit March 24, 2004Printed Name of Person Signing Certificate Jonas Pierre, Sr.

Signature

Total Number of Pages Sent: 7

Attorney: Joel B. German

Reg. No. 48,676

Group Art Unit: Not Yet Known

Examiner: Not Yet Known

TO: Mail Stop Missing Parts
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit
account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**☐ Amendment, 37 CFR _____☐ Fee Transmittal☐ Charge deposit account, in duplicate☐ Petition under 37 CFR _____☐ Extension of Time Petition☒ Other Reply To Notice To Comply With
Requirements For Patent Applications
Containing Nucleotide Sequence And/Or
Amino Acid Sequence Disclosures☒ Statement Regarding Content Of Paper
And Computer Readable Copies And
Reference To Another Application On File
Pursuant To 37 Cfr 1.821(E) And (F)☒ Other Copy Of Notice To Comply With
Requirements For Patent Applications
Containing Nucleotide Sequence And/Or
Amino Acid Sequence Disclosures☐ Maintenance Fee Transmittal

Receipt Confirmed:

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)



MAR 24 2004 3:31PM

AVENTIS US PAT DEPT

NO. 0801 P. 5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
MAURY, et al.

Examiner: Not Yet Known

Art Unit: Not Yet Known

Application No.: 10/726,721

Filed: December 3, 2003

Title: **FEBP1 PROTEIN VECTOR HOST
CELLS AND METHOD FOR MAKING
FEBP1 PROTEIN**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Mail Stop
Sequence, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on

24 March 2004

Date of Deposit

Joel B. German
Signature


STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER
READABLE COPIES AND REFERENCE TO ANOTHER APPLICATION
ON FILE PURSUANT TO 37 C.F.R. 1.821 (e) AND (f)

Mail Stop Missing Parts
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

In compliance with 37 C.F.R. 1.821(e), applicants would like to request transfer of the computer readable form filed in application Serial No. 09/780,996 filed on February 9, 2001, of which the application filed herewith has been designated as a divisional. The computer readable form filed in application Serial No. 09/780,996 was the first and only sequence listing filed in that application.

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821(c), and the computer readable copies required by 37 C.F.R. 1.821 (e), which has above been requested to be transferred from application Serial No. 09/780,996, filed on February 9, 2001, are the same.

Respectfully submitted,


Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626



MAR 24 2004 3:31 PM

AVENTIS US PAT DEPT

NO. 0801 P. 6
Page 1 of 2

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/726,721	12/03/2003	Isabelle Maury	USST08004 US DIV

CONFIRMATION NO. 6368

005487
ROSS J. OEHLER
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807

FORMALITIES LETTER

OC000000012135324

Date Mailed: 03/19/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e); 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4215
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

MAR. 24. 2004 3:31PM

AVENTIS US PAT DEPT

NO. 0801 P. 7
Page 2 of 2

A copy of this notice MUST be returned with the reply.

2. Amended
Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE